Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.48 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.48 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16479517 | 1.00 | POLRMT (0.59) | POLRMTP2RX1P2RX3P2RX2RNASEL | |
| SCHEMBL10153839 | 0.92 | POLRMT (0.61) | POLRMTP2RX1P2RX3P2RX2RNASEL | |
| SCHEMBL4763052 | 0.88 | P2RY2 (0.47) | POLRMTP2RX1P2RX3P2RX2P2RY2 | |
| SCHEMBL4765532 | 0.85 | P2RY2 (0.49) | P2RX1P2RX3IMPDH2P2RY2P2RY1 | |
| SCHEMBL25804330 | 0.82 | POLRMT (0.51) | POLRMTRNASELP2RY2P2RY1SRC | |
| SCHEMBL10149537 | 0.82 | POLRMT (0.56) | POLRMTP2RX1P2RX3P2RX2RNASEL | |
| SCHEMBL23960110 | 0.81 | POLRMT (0.57) | POLRMTP2RX1P2RX3P2RX2RNASEL | |
| SCHEMBL15682895 | 0.81 | POLRMT (0.55) | POLRMTP2RX1P2RX3P2RX2RNASEL | |
| SCHEMBL13519829 | 0.81 | POLRMT (0.55) | POLRMTP2RX1P2RX3P2RX2RNASEL | |
| SCHEMBL16710862 | 0.81 | POLRMT (0.55) | POLRMTP2RX1P2RX3P2RX2RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20140200188-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-07-17 | — | — | US | disclosed |
| WO-2012037038-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200188-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, SLC29A2 | POLRMT 101/4885P2RX1 118/4885P2RX3 193/4885 |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, NSUN2 | POLRMT 103/4885P2RX1 122/4885P2RX3 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.